{"id":"W2610814011","doi":"10.1016/s0140-6736(17)31191-1","title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; University of British Columbia; Queen's University","funders":"British Association of Dermatologists","keywords":"Dupilumab; Eczema Area and Severity Index; Atopic dermatitis; Medicine; Placebo; Concomitant; Clinical endpoint; Dermatology; Dermatology Life Quality Index; Internal medicine; Randomized controlled trial; Placebo-controlled study; Disease; Double blind; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03563158057817713,"score_gpt":0.3192870028795328,"score_spread":0.2836554223013557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}